Amy Medd

Amy Medd is a seasoned professional in oncology market access strategy, currently serving as Senior Director at AstraZeneca since July 1999. In this role, Amy leads teams dedicated to establishing brand value propositions and ensuring patient access to treatments across various oncology therapeutic areas, including immuno-oncology and EGFRm+ NSCLC. Previous positions at AstraZeneca included Senior Director of Oncology Portfolio Contract Strategy and Oncology Access Strategy, where responsibilities encompassed developing impactful market access and pricing strategies as well as managing cross-company collaborations for antibody-drug conjugates. Amy holds an MBA from the University of Delaware and a Master's in Neuroscience from the Medical University of South Carolina, complemented by a Bachelor's degree in Biology from Rutgers University. Prior to AstraZeneca, Amy was a Graduate Research Assistant focused on neurotrophins and age-related hearing loss.